Eli Lilly launches program to boost employer coverage of obesity drugs

Eli Lilly launched an Employer Connect platform to help employers offer obesity drugs at a net price of $449 per month for a multi-dose form of Zepbound and to connect them with third-party administrators; employer coverage of these drugs remains uneven, with many insured people unable to start or stay on treatment.

Eli Lilly launched a new Employer Connect program to help more U.S. employers cover obesity drugs and to address barriers to patient access. The company said list prices for medicines such as Zepbound and Mounjaro top $1,000 per month, and that employer coverage has been uneven. Lilly framed the platform as a way to increase price transparency, offer benefit design flexibility, and let employers choose among independent administrators. The announcement follows moves by Lilly and Novo Nordisk to lower cash prices for their obesity injections. Key details: - Employers using the platform can pay a net discounted price of $449 per month for a new multi-dose form of Zepbound across all doses, and Lilly said this arrangement does not involve rebates. - The platform connects employers with about 15 or more third-party program administrators that help manage benefits and costs; the company said administrators include firms such as GoodRx, Mark Cuban's Cost Plus Drug Company, Teladoc Health and Calibrate Health. - Employers can select among administrators to design benefits that fit their budgets and workforce, with some administrators focused on enrollment and claims and others offering broader obesity management services such as telehealth and nutrition support. - Lilly said roughly half of people with commercial insurance are unable to start or stay on treatment because employer coverage is uneven. - A Peterson-KFF Health System Tracker survey cited by the company found nearly one-fifth of firms with over 200 workers, and 43% of firms with 5,000 or more workers, reported covering GLP-1 drugs for weight loss as of October. - Lilly and Novo Nordisk also reached deals tied to expanded Medicare coverage for these medicines, and Medicare coverage was reported as planned for later this year. Summary: The Employer Connect program aims to broaden employee access while giving employers clearer pricing and more options for administering benefits. Lilly said some employers might opt into coverage in the coming months while others could wait until 2027, and the company plans to expand the number of administrators on the platform. The overall impact will depend on employer decisions and program uptake in the months ahead.